The Wegovy label lists acute pancreatitis in the Warnings and Precautions section. The reported incidence in clinical studies is low, but not zero.

Acute pancreatitis is a labeled warning for semaglutide and tirzepatide products. It has been reported in both diabetes-treatment and weight-management trial or label contexts, but this source check did not find a stratified analysis proving that risk is independent of diabetes status.

The classic presentation is severe persistent abdominal pain, often radiating to the back, sometimes with nausea and vomiting.

That isn't the routine GI side-effect pattern. It's the symptom that pulls the peptide out of "feels normal" and into "needs evaluation."